GDTC CytoMed Therapeutics: Bozor kapitallashuvining balans qiymatiga nisbati

w2.cytomed.sg (GDTC) - korporativ logo

Onkologik hujayralar terapiyasi YaIM sikllaridan mustaqildir, bu esa emitentning moliyaviy holati tadqiqot natijalari bilan belgilanishini anglatadi, bunda joriy ko'rsatkich 2.79 darajasida turibdi. CytoMed Therapeutics (GDTC) kompaniyasining ushbu narxlar grafigi mualliflik protokollari asosida NK va γδ T-hujayralariga asoslangan davolash tizimini ishlab chiqayotgan kompaniyaning samaradorligini aks ettiradi. Biznes hozirda platforma xavfsizligini tasdiqlash va sog'liqni saqlash gigantlari orasidan hamkorlarni aniqlash uchun allogeneik usullarning I bosqich sinovlariga e'tibor qaratmoqda.

CytoMed Therapeutics Limited (GDTC) - Bozor kapitallashuvining balans qiymatiga nisbati 21.02.2024dan 28.10.2026gacha

GDTC (CytoMed Therapeutics): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi w2.cytomed.sg|GDTC - Konsensus maqsadli narx
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi CytoMed|GDTC - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati CytoMed Therapeutics|GDTC - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati w2.cytomed.sg|GDTC - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati CytoMed Therapeutics|GDTC - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati w2.cytomed.sg|GDTC - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati CytoMed
Fundamental baholash:GDTC (CytoMed Therapeutics Ltd)
CytoMed Therapeutics tayyor mahsulotlari

CytoMed Therapeutics (GDTC) kompaniyasi barqarorligining fundamental omillarini aniqlash uchun sof aktivlar qiymatini baholash juda muhimdir. Ushbu ko'rsatkich kompaniyaning joriy bozor qiymatini uning o'z kapitaliga bo'lish orqali hisoblanadi. Narxning buki ko'paytirgichi tendentsiyasi bozorning biznesning haqiqiy resurslarini haddan tashqari yuqori yoki past baholaganini aks ettiradi. Bioteknologiya sektori uchun bu qimmat va energiyatejam saqlash tizimlarining kapitalizatsiyasini ifodalaydi. Investorlar ushbu o'sishni qat'iy ESG xavfsizlik protokollarini joriy qilish xarajatlari bilan solishtirib baholashlari kerak.

Asosiy raqobatchilar

ONC (BeiGene Ltd) - Bozor kapitallashuvining balans qiymatiga nisbati|halozyme.com (HALO) - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati RVMD|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati URGN (UroGen Pharma Corp)|BCAX - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati personalis.com PSNL|ERAS: Bozor kapitallashuvining balans qiymatiga nisbati|DCTH - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati YMAB|AURA (Aura Corp) - Bozor qiymatining balans qiymatiga koeffitsiyenti|CADL - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Bozor kapitallashuvining balans qiymatiga nisbati|HURA - Kapitallashuvning sof aktivlarga nisbati|Protara Therapeutics - Kapitallashuvning sof aktivlarga nisbati|FATE: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati aadibio.com WHWK|TScan Therapeutics, Inc. (TCRX) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati CSBR (Champions Oncology Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti XBiotech USA|Bozor kapitallashuvining balans qiymatiga nisbati CVM (CEL-SCI Corporation)|Kapitallashuvning sof aktivlarga nisbati ostherapies.com OSTX|RADX: Kapitallashuvning sof aktivlarga nisbati|ARTV - Bozor qiymatining balans qiymatiga koeffitsiyenti|Kapitallashuvning sof aktivlarga nisbati Adlai Nortye Limited ANL|VERU: Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor qiymatining balans qiymatiga nisbati TPST|XLO (Xilio Therapeutics) - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati RENB|Kapitallashuvning sof aktivlarga nisbati Mural Bio|Kairos Pharma Ltd - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti onkuretherapeutics.com (OKUR)|CRIS - Bozor kapitallashuvining balans qiymatiga nisbati|APLM - Kapitallashuvning balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Tharimmune (THAR)|Advanced Biomed Inc (ADVB) - Balans qiymatiga nisbatan bozor qiymati|GNPX - Kapitallashuvning sof aktivlarga nisbati|Calidi Biotherapeutics, Inc. (CLDI) - Bozor kapitallashuvining balans qiymatiga multiplikatori|SBFM - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Xenetic Bio|Salarius Pharmaceuticals, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti PPBT (Purple Biotech Ltd)|Bozor qiymatining balans qiymatiga nisbati American Oncology Network, Inc.|Balans qiymatiga nisbatan bozor qiymati BeiGene Ltd BGNE|Checkpoint Therapeutics - Bozor kapitallashuvining balans qiymatiga nisbati|ELEV: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati icadmed.com (ICAD)|Ikena Oncology (IKNA) - Sof aktivlarga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati NTBL (Notable Labs Inc.)|Bozor qiymatining balans qiymatiga koeffitsiyenti Viracta (VIRX)|Kapitallashuvning sof aktivlarga nisbati MOR|Bozor kapitallashuvining balans qiymatiga nisbati nayabiosciences.com NAYA|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma (AAPGV)